Prevention and treatment of glucocorticoid-induced osteoporosis

Therapeutics

Abstract

Glucocorticoids continue to be used for many inflammatory diseases, and glucocorticoid-induced osteoporosis (GIOP) remains the most common secondary form of metabolic bone disease. Recent meta-analyses suggest that both active and native vitamin D can help maintain lumbar spine bone mineral density (BMD), particularly in patients receiving lower-dose glucocorticoid therapy. Recent randomized, controlled clinical trials have shown that oral bisphosphonates are superior to vitamin D in maintaining BMD and should be continued for as long as a person receives glucocorticoid treatment. Similar to the oral bisphosphonates, intravenous ibandronate has been shown to preserve BMD and also to significantly reduce vertebral fracture risk. Increasing evidence supports a role for parathyroid hormone to prevent or treat GIOP as well. Despite effective therapies, many at-risk patients fail to receive treatment for GIOP, and even among those who initiate treatment, half discontinue within 1 to 2 years. New approaches to evidence implementation are being tested to improve the quality of osteoporosis care and decrease fracture risk among long-term glucocorticoid users.

References and Recommended Reading

  1. 1.
    Kirwan JR, Arthritis and Rheumatism Council Low Dose glucocorticoid Study Group:The effect of glucocorticoids on joint destruction in rheumatoid arthritis.N Engl J Med 1995,333:142–146.PubMedCrossRefGoogle Scholar
  2. 2.
    van Everdingen AA, Jacobs JWG, van Reesema DR, Bijlsma JWJ:Low dose prednisone therapy for patients with early active rheumatoid arthritis: clinical efficacy, disease modifying properties and side effects. A double-blind placebo-controlled clinical trial.Ann Intern Med 2002,136:1–12.PubMedGoogle Scholar
  3. 3.
    Bijlsma JW, Hoes JN, van Everdingen AA, et al.:Are glucocorticoids DMARDs? Ann N Y Acad Sci 2006,1069:268–274.PubMedCrossRefGoogle Scholar
  4. 4.
    Saag KG, Koehnke R, Caldwell JR, et al.:Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events.Am J Med 1994,96:115–123.PubMedCrossRefGoogle Scholar
  5. 5.
    Curtis JR, Westfall AO, Allison J, et al.:Population-based assessment of adverse events associated with long-term glucocorticoid use.Arthritis Rheum 2006,55:420–426.PubMedCrossRefGoogle Scholar
  6. 6.
    Of major importance de Nijs RN, Jacobs JW, Lems WF, et al.:Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis.N Engl J Med 2006,355:675–684. Randomized controlled trial comparing alendronate versus activated vitamin D among low-dose glucocorticoid users.PubMedCrossRefGoogle Scholar
  7. 7.
    van Staa TP, Geusens P, Bijlsma JW, et al.:Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis.Arthritis Rheum 2006,54:3104–3112.PubMedCrossRefGoogle Scholar
  8. 8.
    van Staa T, Leufkens H, Abenhaim L, et al.:Use of oral corticosteroids and risk of fractures.J Bone Miner Res 2000,15:993–1000.PubMedCrossRefGoogle Scholar
  9. 9.
    Da Silva JA, Jacobs JW, Kirwan JR, et al.:Safety of low dose glucocorticoid treatment in rheumatoid arthritis: published evidence and prospective trial data.Ann Rheum Dis 2006,65:285–293.PubMedCrossRefGoogle Scholar
  10. 10.
    Adachi JD, Olszynski WP, Hanley DA, et al.:Management of corticosteroid-induced osteoporosis [review].Semin Arthritis Rheum 2000,29:228–251.PubMedCrossRefGoogle Scholar
  11. 11.
    Adler R, Hochberg MC:Suggested guidelines for evaluation and treatment of glucocorticoid-induced osteoporosis for the Department of Veterans Affairs.Arch Intern Med 2003,163:2619–2624.PubMedCrossRefGoogle Scholar
  12. 12.
    American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis.Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.Arthritis Rheum 2001,44:1496–1503.CrossRefGoogle Scholar
  13. 13.
    Bone and Tooth Society of Great Britain:Glucocorticoid-Induced Osteoporosis: Guidelines for Prevention and Treatment. London: Royal College of Physicians of London; 2002.Google Scholar
  14. 14.
    Geusens P, de Nijs RNJ, Lems WF, et al.:Prevention of glucocorticoid osteoporosis: a consensus document of the Dutch Society for Rheumatology.Ann Rheum Dis 2004,63:324–325.PubMedCrossRefGoogle Scholar
  15. 15.
    Of importance Devogelaer JP, Goemaere S, Boonen S, et al.:Evidence-based guidelines for the prevention and treatment of glucocorticoid-induced osteoporosis: a consensus document of the Belgian Bone Club.Osteoporos Int 2006,17:8–19. Comprehensive evidence synthesis and updated recommendations regarding GIOP management.PubMedCrossRefGoogle Scholar
  16. 16.
    Nawata H, Soen S, Takayanagi R, et al.:Guidelines on the management and treatment of glucocorticoid-induced osteoporosis of the Japanese Society for Bone and Mineral Research (2004),J Bone Miner Metab 2005,23:105–109.PubMedCrossRefGoogle Scholar
  17. 17.
    Lane N, Goldring S, Stewart J, Morris S:Biochemical markers of bone turnover in glucocorticoid treated patients are altered by calcium supplementation: preliminary results from the ACTIVATE trial.Arthritis Rheum 2003,48:S498.CrossRefGoogle Scholar
  18. 18.
    Sambrook PN:Corticosteroid osteoporosis: practical implications of recent trials.J Bone Min Res 2000,15:1645–1649.CrossRefGoogle Scholar
  19. 19.
    Amin S, LaValley MP, Simms RW, Felson DT:The role of vitamin D in corticosteroid-induced osteoporosis.Arthritis Rheum 1999,42:1740–1751.PubMedCrossRefGoogle Scholar
  20. 20.
    Wallach S, Cohen S, Reid DM, et al.:Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy.Calcif Tissue Int 2000,67:277–285.PubMedCrossRefGoogle Scholar
  21. 21.
    Adachi R, Saag K, Emkey R, et al.:Effects of alendronate for two years on BMD and fractures in patients receiving glucocorticoids.Arthritis Rheum 2001,44:202–211.PubMedCrossRefGoogle Scholar
  22. 22.
    Saag KG, Emkey R, Schnitzer T, et al.:Alendronate for the treatment and prevention of glucocorticoid-induced osteoporosis.N Engl J Med 1998,339:292–299.PubMedCrossRefGoogle Scholar
  23. 23.
    Reid DM, Hughes R, Laan RF:Efficacy and safety of daily risedronate in the treatment of corticosteroid-induced osteoporosis in men and women: a randomized trial.J Bone Min Res 2000,15:1006–1013.CrossRefGoogle Scholar
  24. 24.
    Sambrook P, Birmingham J, Kelly P, et al.:Prevention of corticosteroid osteoporosis. A comparison of calcium, calcitriol, and calcitonin.N Engl J Med 1993,328:1747–1752.PubMedCrossRefGoogle Scholar
  25. 25.
    Dykman T, Haralson K, Gluck O, et al.:Effect of oral 1,25-dihydroxyvitamin D and calcium on glucocorticoid-induced osteopenia in patients with rheumatic diseases.Arthritis Rheum 1984,27:1336–1343.PubMedCrossRefGoogle Scholar
  26. 26.
    Braun JJ, Birkenhager-Frenkel DH, Rietveld AH, et al.:Influence of 1 alpha-(OH)D3 administration on bone and bone mineral metabolism in patients on chronic glucocorticoid treatment; a double blind controlled study.Clin Endocrinol 1983,18:265–273.CrossRefGoogle Scholar
  27. 27.
    Reginster JY, Kuntz D, Verdickt W, et al.:Prophylactic use of alfacalcidol in corticosteroid-induced osteoporosis.Osteoporos Int 1999,9:75–81.PubMedCrossRefGoogle Scholar
  28. 28.
    Bijlsma JWJ, Raymakers JA, Mosch C, et al.:Effect of oral calcium and vitamin D on glucocorticoid-induced osteopenia.Clin Exper Rheumatol 1988,6:113–119.Google Scholar
  29. 29.
    Richy F, Ethgen O, Bruyere O, Reginster JY:Efficacy of alphacalcidol and calcitriol in primary and corticosteroid-induced osteoporosis: a meta-analysis of their effects on bone mineral density and fracture rate.Osteoporos Int 2004,15:301–310.PubMedCrossRefGoogle Scholar
  30. 30.
    Richy F, Schacht E, Bruyere O, et al.:Vitamin D analogs versus native vitamin D in preventing bone loss and osteoporosis-related fractures: a comparative meta-analysis.Calcif Tissue Int 2005,76:176–186.PubMedCrossRefGoogle Scholar
  31. 31.
    Of importance de Nijs RN, Jacobs JW, Algra A, et al.:Prevention and treatment of glucocorticoid-induced osteoporosis with active vitamin D3 analogues: a review with meta-analysis of randomized controlled trials including organ transplantation studies.osteoporos Int 2004,15:589–602. Meta-analyses comparing the effects of vitamin D preparations with the effects of calcium alone, no treatment, and bisphosphonates on BMD change and the risk of fractures.PubMedCrossRefGoogle Scholar
  32. 32.
    Ringe J, Coster A, Meng T, et al.:Treatment of glucocorticoid-induced osteoporosis with alfacalcidol/calcium versus vitamin D/calcium.Calcif Tissue Int 1999,65:337–340.PubMedCrossRefGoogle Scholar
  33. 33.
    Ringe J, Dorst A, Faber H, et al.:Superiority of alfacalcidol over plain vitamin D in the treatment of glucocorticoid-induced osteoporosis.Rheumatology Int 2004,24:63–70.CrossRefGoogle Scholar
  34. 34.
    Sambrook PN, Kotowicz M, Nash P, et al.:Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.J Bone Miner Res 2003,18:919–924.PubMedCrossRefGoogle Scholar
  35. 35.
    Lems WF, Lodder MC, Lips P, et al.:Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebocontrolled trial.Osteoporos Int 2006,17:716–723.PubMedCrossRefGoogle Scholar
  36. 36.
    Cohen S, Levy RM, Keller M, et al.:Risedronate therapy prevents corticosteroid-induced bone loss: A twelve-month, multicenter, randomized, double-blind, placebo-contrlled, parallel-group study.Arthritis Rheum 1999,42:2309–2318.PubMedCrossRefGoogle Scholar
  37. 37.
    Emkey R, Delmas PD, Goemaere S, et al.:Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.Arthritis Rheum 2003,48:1102–1108.PubMedCrossRefGoogle Scholar
  38. 38.
    Ringe JD, Dorst A, Faber H, et al.:Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study.Osteoporos Int 2003,14:801–807.PubMedCrossRefGoogle Scholar
  39. 39.
    Ringe JD, Dorst A, Faber H, et al.:Three-monthly ibandronate bolus injection offers favourable tolerability and sustained efficacy advantage over two years in established corticosteroid-induced osteoporosis.Rheumatology (Oxford) 2003,42:743–749.CrossRefGoogle Scholar
  40. 40.
    Campbell IA, Douglas JG, Francis RM, et al.:Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids.Thorax 2004,59:761–768.PubMedCrossRefGoogle Scholar
  41. 41.
    van Staa TP, Leufkens HG, Cooper C:Use of inhaled corticosteroids and risk of fractures.J Bone Miner Res 2001,16:581–588.PubMedCrossRefGoogle Scholar
  42. 42.
    Lane N, Sanchez S, Modin G, et al.:Bone mass continues to increase at the hip after parathyroid hormone treatment is discontinued in glucocorticoid induced osteoporosis: results of a randomized controlled clinical trial.J Bone Min Res 2000,15:944–951.CrossRefGoogle Scholar
  43. 43.
    Lane NE, Sanchez S, Modin GW, et al.:Parathyroid hormone treatment can reverse corticosteroid-induced osteoporosis. Results of a randomized controlled clinical trial.J Clin Invest 1998,102:1627–1633.PubMedCrossRefGoogle Scholar
  44. 44.
    Oxlund H, Ortoft G, Thomsen JS, et al.:The anabolic effect of PTH on bone is attenuated by simultaneous glucocorticoid treatment.Bone 2006,39:244–252.PubMedCrossRefGoogle Scholar
  45. 45.
    Rehman Q, Lang T, Arnaud C, et al.:Daily treatment with parathyroid hormone is associated with an increase in vertebral cross-sectional area in postmenopausal women with glucocorticoid-induced osteoporosis.Osteoporos Int 2003,14:77–81.PubMedCrossRefGoogle Scholar
  46. 46.
    Shiraki M, Shiraki Y, Aoki C, Miura M:Vitamin K2 (menatetrenone) effectively prevents fractures and sustains lumbar bone mineral density in osteoporosis.J Bone Miner Res 2000,15:515–521.PubMedCrossRefGoogle Scholar
  47. 47.
    Koshihara Y, Hoshi K, Okawara R, et al.:Vitamin K stimulates osteoblastogenesis and inhibits osteoclastogenesis in human bone marrow cell culture.J Endocrinol 2003,176:339–348.PubMedCrossRefGoogle Scholar
  48. 48.
    Yonemura K, Kimura M, Miyaji T, Hishida A:Short-term effect of vitamin K administration on prednisolone-induced loss of bone mineral density in patients with chronic glomerulonephritis.Calcif Tissue Int 2000,66:123–128.PubMedCrossRefGoogle Scholar
  49. 49.
    Sasaki N, Kusano E, Takahashi H, et al.:Vitamin K2 inhibits glucocorticoid-induced bone loss partly by preventing the reduction of osteoprotegerin (OPG).J Bone Miner Metab 2005,23:41–47.PubMedCrossRefGoogle Scholar
  50. 50.
    Sasaki N, Kusano E, Ando Y, et al.:Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis.Nephrol Dial Transplant 2001,16:479–482.PubMedCrossRefGoogle Scholar
  51. 51.
    Hofbauer LC, Gori F, Riggs BL, et al.:Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis.Endocrinology 1999,140:4382–4389.PubMedCrossRefGoogle Scholar
  52. 52.
    van Everdingen AA, Siewertsz van Reesema DR, Jacobs JW, Bijlsma JW:Low-dose glucocorticoids in early rheumatoid arthritis: discordant effects on bone mineral density and fractures? Clin Exp Rheumatol 2003,21:155–160.PubMedGoogle Scholar
  53. 53.
    van Staa T, Leufkens H, Cooper C:The epidemiology of corticosteroid induced osteoporosis: a meta-analysis.Osteoporos Int 2002,13:777–787.PubMedCrossRefGoogle Scholar
  54. 54.
    van Staa TP, Laan RF, Barton IP, et al.:Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy.Arthritis Rheum 2003,48:3224–3229.PubMedCrossRefGoogle Scholar
  55. 55.
    van Staa TP, Leufkens HGM, Abenhaim L, et al.:Oral corticosteroids and fracture risk: relationship to daily and cumulative doses.Rheumatology (Oxford) 2000,39:1383–1389.CrossRefGoogle Scholar
  56. 56.
    American College of Rheumatology Task Force on Osteoporosis Guidelines:Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis.Arthritis Rheum 1996,39:1791–1801.CrossRefGoogle Scholar
  57. 57.
    van Staa T, Eastell R, Barton IP, et al.:The value of bone turnover markers in the prediction of vertebral fracture in patients using oral glucocorticoids [abstract].J Bone Miner Res 2003,18:S66.CrossRefGoogle Scholar
  58. 58.
    Eastell R, Barton I, Hannon R, et al.:Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate.J Bone Miner Res 2003,18:1051–1056.PubMedCrossRefGoogle Scholar
  59. 59.
    Simonelli C, Killeen K, Mehle S, Swanson L:Barriers to osteoporosis identification and treatment among primary care physicians and orthopedic surgeons.Mayo Clin Proc 2002,77:334–338.PubMedCrossRefGoogle Scholar
  60. 60.
    Of importance van Staa TP, Geusens P, Zhang B, et al.:Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids.Rheumatology (Oxford) 2006, Epub ahead of print. Identifies subgroups of patients using long-term glucocorticoids for whom prescription therapy for GIOP is likely to be most cost-effective.Google Scholar
  61. 61.
    Of importance Curtis JR, Wesfall AO, Allison JJ, et al.:Channeling and adherence with alendronate and risedronate among chronic glucocorticoid users.Osteoporos Int 2006,17:1268–1274. Highlights poor long-term compliance with bisphosphonate therapy among long-term glucocorticoid users.PubMedCrossRefGoogle Scholar
  62. 62.
    Walsh LJ, Wong CA, Pringle M, Tattersfield AE:Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study.BMJ 1996,313:344–346.PubMedGoogle Scholar
  63. 63.
    Buckley LM, Marquez M, Feezor R, et al.:Prevention of corticosteroid-induced osteoporosis: results of a patient survey.Arthritis Rheum 1999,42:1736–1739.PubMedCrossRefGoogle Scholar
  64. 64.
    Mudano A, Allison J, Hill J, et al.:Variations in glucocorticoid induced osteoporosis prevention in a managed care cohort.J Rheumatol 2001,28:1298–1305.PubMedGoogle Scholar
  65. 65.
    Gudbjornsson B, Juliusson UI, Gudjonsson FV:Prevalence of long term steroid treatment and the frequency of decision making to prevent steroid induced osteoporosis in daily clinical practice.Ann Rheum Dis 2002,61:32–36.PubMedCrossRefGoogle Scholar
  66. 66.
    Solomon DH, Katz J, Jacobs JW, et al.:Management of glucocorticoid induced osteoporosis in patients with rheumatoid arthritis.Arthritis Rheum 2002,46:3136–3142.PubMedCrossRefGoogle Scholar
  67. 67.
    Ramsey-Goldman R:Missed opportunities in physician management of glucocorticoid-induced osteoporosis? Arthritis Rheum 2002,46:3115–3120.PubMedCrossRefGoogle Scholar
  68. 68.
    Saag KG, Gehlbach SH, Curtis JR, et al.:Trends in prevention of glucocorticoid-induced osteoporosis.J Rheumatol 2006,33:1651–1657.PubMedGoogle Scholar
  69. 69.
    Curtis JR, Westfall AO, Allison JJ, et al.:Longitudinal patterns in the prevention of osteoporosis in glucocorticoid-treated patients.Arthritis Rheum 2005,52:2485–2494.PubMedCrossRefGoogle Scholar
  70. 70.
    Chantler IW, Davie MW, Evans SF, Rees JS:Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service.Ann Rheum Dis 2003,62:350–352.PubMedCrossRefGoogle Scholar
  71. 71.
    Rosen HN, Rosenblatt M:Prevention and treatment of glucocorticoid-induced osteoporosis. InUp To Date, vol. 11, no. 1. Edited by Rose B. Wellesley, MA: UpToDate; 2003.Google Scholar
  72. 72.
    Buckley LM, Marquez M, Hudson JO, et al.:Variations in physician perceptions of the risk of osteoporosis in corticosteroid users by physician specialty.J Rheumatol 1998,25:2195–2202.PubMedGoogle Scholar
  73. 73.
    Blalock SJ, Norton LL, Patel RA, Dooley MA:Patient knowledge, beliefs, and behavior concerning the prevention and treatment of glucocorticoid-induced osteoporosis.Arthritis Rheum 2005,53:732–739.PubMedCrossRefGoogle Scholar
  74. 74.
    Liu RH, Albrecht J, Werth VP:Cross-sectional study of bisphosphonate use in dermatology patients receiving long-term oral corticosteroid therapy.Arch Dermatol 2006,142:37–41.PubMedCrossRefGoogle Scholar
  75. 75.
    Naunton M, Peterson GM, Jones G, et al.:Multifaceted educational program increases prescribing of preventive medication for corticosteroid induced osteoporosis.J Rheumatol 2004,31:550–556.PubMedGoogle Scholar
  76. 76.
    Solomon DH, Katz JN, La Tourette AM, Coblyn JS:Multifaceted intervention to improve rheumatologists’ management of glucocorticoid-induced osteoporosis: a randomized controlled trial.Arthritis Rheum 2004,51:383–387.PubMedCrossRefGoogle Scholar
  77. 77.
    McDonough RP, Doucette WR, Kumbera P, Klepser DG:An evaluation of managing and educating patients on the risk of glucocorticoid-induced osteoporosis.Value Health 2005,8:24–31.PubMedCrossRefGoogle Scholar
  78. 78.
    Kiefe CI, Allison JJ, Williams OD, et al.:Improving quality improvement using achievable benchmarks for physician feedback: a randomized controlled trial.JAMA 2001,285:2871–2879.PubMedCrossRefGoogle Scholar
  79. 79.
    Curtis JR, Westfali AO, Allison JJ, et al.: Challenges in improving the quality of osteoporosis care for long term glucocorticoid users: a prospective, randomized trial.Arch Intern Med. In press.Google Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.University of Alabama at BirminghamBirminghamUSA

Personalised recommendations